Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases

Project description

The making of a multinational, adaptive European COVID-19 trial network

The emergence of the COVID-19 pandemic has demonstrated the necessity of improving the global clinical trial capacity based on the cooperation between the EU and international partners. DisCoVeRy (WP1), designed as a multi-arm adaptive repurposing trial, can be expanded to several European countries with adequate multinational financing and trial management capacity. The EU-funded EU-RESPONSE project will establish a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, taking advantage of the existing initiatives, allowing the European expansion of DisCoVeRy (WP1) and the creation of a COVID-19 adaptive platform trial (WP2). The project will produce solid evidence for drug repurposing or registration, permitting most European hospitals to participate at their preferred level of commitment in establishing a network of investigation sites within the EU and associated countries.

Objective

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and expertise, allowing European expansion of DisCoVeRy (WP1) and the establishment of a COVID19 adaptive platform trial (WP2). The DisCoVeRy trial, designed as a multi-arm adaptive repurposing trial, initiated in France, has the potential to expand to many other European countries with appropriate support in terms of multinational funding and trial management capacity. This will complete the evaluation of repurposed drugs, while building a European clinical trial network which, together with other European networks such as the Solidarity trial, will design and run a new European platform trial. EU-RESPONSE will swiftly generate robust evidence for drug repurposing or registration, through a modular trial framework allowing most European hospitals to participate at their preferred level of commitment, thus building a network of investigation sites within European and associated countries. Cooperation with other European platforms, in particular the RECOVER consortium platform will be achieved through a joint coordination mechanism aligned with European and national policies (WP3), ensuring a coordinated strategy for the European COVID-19 Adaptive Platform Trials, their complementarity in providing access for requests for a new domain or arm, their synergy and cross-fertilization through the development of a common toolbox for the development and the management of Adaptive Platform Trials. Joining forces in Europe and with international partners, it will contribute to the global clinical trial capacity for urgently meeting the expectations of society and developers. It will also boost multinational cooperation in Europe and promote the establishment of adaptive platform trials in other diseases, and will have a major impact on epidemic control.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 6 146 115,27
Address
RUE DE TOLBIAC 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 6 176 115,27

Participants (26)